Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.
about
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortalityCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersCandidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesEstimation of average diagnosis and treatment costs of hepatitis C.Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitalsReasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study.Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections.Hepatitis C: is a vaccine the solution?Controversies in and challenges to our understanding of hepatitis C.The costs of breast cancer in a Mexican public health institution.Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness.Prisons and HCV: a review and a report on an experience in New South Wales Australia.Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.Protease inhibitors for hepatitis C: economic implications.Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature.Attitudes and Awareness Regarding Hepatitis B and Hepatitis C Amongst Health-care Workers of a Tertiary Hospital in India.Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients.High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil.A balancing view: We cannot do it alone.A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
P2860
Q27488220-1B349290-16DA-4392-A014-281B443FE39BQ28483820-E97617C2-8E93-4A64-94A1-94CD92613E4AQ30226978-045F1B6C-9D85-4420-ABF1-B129154819C2Q33596466-B51522D3-4301-4E0D-8CF0-D9B9874D5ECEQ33607231-0A05878C-234B-40BB-9010-9D9327E36225Q33898300-0D25AD2D-38A8-4387-B942-B1EB4ADFFCCFQ33974105-6EE42353-379A-486F-8C31-B49A7230759CQ34290831-3C1340A4-C92A-4165-8C81-437C62B85A57Q34604806-1A62359B-CAB9-40ED-85A7-7AE4B3A0F3F0Q35727419-AC51D7AC-F894-4C92-9725-F38D75739866Q36301576-F44698D9-5B9F-43C4-A151-CC660D49F602Q36799786-79BDA65E-80C0-40A0-94AE-D2D660D2AED4Q37242489-93EFE78F-8E1A-41ED-9100-6AA079810DDEQ38050834-244619CA-5549-4B77-AAB7-F5BAB6106BBFQ38120496-0CB59247-73D8-42C0-A83E-563C74EDD89AQ38206573-A1127EAA-55BB-4468-A617-F39E648CE30CQ42093708-44B51401-337C-4CFF-9019-4D96AEAEC8A8Q42177592-503E6208-371A-40C2-AF0C-0B3E8BB87289Q42991146-35372F23-DBE9-455F-AAC8-DDB2F19EEC06Q43038208-A19A5D14-EA59-46D0-9E82-8C8442A2638FQ43048365-AC73BBDC-3D06-4BB0-B96E-11F52796B611Q44931846-7FF8FC0C-FFAD-45CD-84DB-A47DFCEEF685Q52306466-30653E93-B55B-491E-BC21-8A37A94229E6
P2860
Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@ast
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en-gb
type
label
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@ast
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en-gb
prefLabel
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@ast
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en-gb
P2860
P1433
P1476
Hepatitis C: cost of illness a ...... uation of antiviral therapies.
@en
P2093
John B Wong
P2860
P304
P356
10.2165/00019053-200624070-00005
P577
2006-01-01T00:00:00Z
P6179
1049006742